Cell Reports · 2020 · 83 citations · 31 references
MedicineCancer BiologyMolecular GeneticsCell SignalingSignal TransductionTumor ProgressionCancer Cell SignalingMtor Inhibitor TherapyNoncoding Rna In CancerSignal Transduction In CancerTherapeutic ResistanceTumor Suppressor GenesBreast Cancer Resistance MechanismsEndocrine ResistanceHormone Resistance MechanismsMalignant ProgressionMtor InhibitionMtor SignalingTherapeutic Resistance MechanismsTriple-negative Breast Cancer Therapy
Epigenomic alterations can give rise to various tumor-promoting properties, including therapeutic resistance of cancer cells. Here, we identify an lncRNA, BDNF-AS, whose overexpression is specifically driven by a MEF2A-regulated enhancer in endocrine-resistant and triple-negative breast cancer (TNBC). High levels of BDNF-AS in breast cancer tissues not only feature endocrine resistance in hormone receptor (HR)-positive patients but also correlate with poor outcomes in both HR-positive and TNBC patients. Mechanistically, BDNF-AS acts as a molecular scaffold to promote RNH1 protein degradation via TRIM21-mediated ubiquitination of RNH1 at K225. Subsequently, BDNF-AS abolishes RNH1-regulated and RISC-mediated mTOR mRNA decay, therefore sustaining the activation of mTOR signaling. Importantly, mTOR inhibitor, but not PI3K inhibitor, could reverse tamoxifen resistance induced by the overexpression of BDNF-AS. These results point toward a master regulatory role of an enhancer-activated cascade of BDNF-AS/RNH1/TRIM21/mTOR in endocrine resistance and malignant progression of breast cancer.
31
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals
Mitchell Guttman, Ido Amit, Manuel Garber et al. · Nature · 2009 · 4.2K citations · Full text
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine · 2016 · 2.9K citations
Medicine, Oncology, Pharmacology +17
Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations
Medicine, Oncology, Pharmacology +17
The PIK3CA gene is mutated with high frequency in human breast cancers
Kurtis E. Bachman, Pedram Argani, Yardena Samuels et al. · Cancer Biology & Therapy · 2004 · 664 citations · Full text